Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies.

Vaqué JP, Martínez N, Batlle-López A, Pérez C, Montes-Moreno S, Sánchez-Beato M, Piris MA.

Haematologica. 2014 Feb;99(2):222-31. doi: 10.3324/haematol.2013.096248. Review.

2.

[Molecular biology of malignant lymphomas for non-specialists].

Novak U.

Ther Umsch. 2010 Oct;67(10):501-4. doi: 10.1024/0040-5930/a000085. Review. German.

PMID:
20886455
3.

Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia.

Ferreira BI, García JF, Suela J, Mollejo M, Camacho FI, Carro A, Montes S, Piris MA, Cigudosa JC.

Haematologica. 2008 May;93(5):670-9. doi: 10.3324/haematol.12221. Epub 2008 Mar 26.

4.

Functional signatures identified in B-cell non-Hodgkin lymphoma profiles.

Aggarwal M, Sánchez-Beato M, Gómez-López G, Al-Shahrour F, Martínez N, Rodríguez A, Ruiz-Ballesteros E, Camacho FI, Pérez-Rosado A, de la Cueva P, Artiga MJ, Pisano DG, Kimby E, Dopazo J, Villuendas R, Piris MA.

Leuk Lymphoma. 2009 Oct;50(10):1699-708.

PMID:
19863341
5.

A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.

Dietel M, Jöhrens K, Laffert MV, Hummel M, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I.

Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11. Review.

PMID:
26358176
6.

Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma.

Waibel M, Gregory G, Shortt J, Johnstone RW.

Curr Opin Hematol. 2014 Jul;21(4):297-308. doi: 10.1097/MOH.0000000000000045. Review.

PMID:
24811162
7.

Molecular features of B-cell lymphoma.

Siebert R, Rosenwald A, Staudt LM, Morris SW.

Curr Opin Oncol. 2001 Sep;13(5):316-24. Review.

PMID:
11555707
8.

Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.

Malpeli G, Barbi S, Moore PS, Scardoni M, Chilosi M, Scarpa A, Menestrina F.

Haematologica. 2004 Sep;89(9):1091-9.

9.

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.

Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD.

Nature. 2011 Mar 17;471(7338):377-81. doi: 10.1038/nature09754. Epub 2011 Mar 2.

10.

Translation deregulation in B-cell lymphomas.

Horvilleur E, Wilson LA, Willis AE.

Biochem Soc Trans. 2010 Dec;38(6):1593-7. doi: 10.1042/BST0381593.

PMID:
21118132
11.

MicroRNA profiling of Epstein-Barr virus-associated NK/T-cell lymphomas by deep sequencing.

Motsch N, Alles J, Imig J, Zhu J, Barth S, Reineke T, Tinguely M, Cogliatti S, Dueck A, Meister G, Renner C, Grässer FA.

PLoS One. 2012;7(8):e42193. doi: 10.1371/journal.pone.0042193. Epub 2012 Aug 3.

12.

The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas.

Di Lisio L, Martinez N, Montes-Moreno S, Piris-Villaespesa M, Sanchez-Beato M, Piris MA.

Blood. 2012 Aug 30;120(9):1782-90. doi: 10.1182/blood-2012-05-402784. Epub 2012 Jul 3. Review.

13.

Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Li C, Kim SW, Rai D, Bolla AR, Adhvaryu S, Kinney MC, Robetorye RS, Aguiar RC.

Blood. 2009 Jun 25;113(26):6681-90. doi: 10.1182/blood-2009-01-202028. Epub 2009 Mar 10.

14.

The molecular pathogenesis of B-cell non-Hodgkin lymphoma.

Blombery PA, Wall M, Seymour JF.

Eur J Haematol. 2015 Oct;95(4):280-93. doi: 10.1111/ejh.12589. Epub 2015 Jun 9. Review.

PMID:
25996166
15.

[Molecular abnormalities in lymphomas].

Delsol G.

Bull Cancer. 2010 Nov;97(11):1347-64. doi: 10.1684/bdc.2010.1214. Review. French.

16.

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Küppers R, Lenze D, Ott G, Pott C, Richter J, Rosenwald A, Szczepanowski M, Schwaenen C, Stein H, Trautmann H, Wessendorf S, Trümper L, Loeffler M, Spang R, Kluin PM, Klapper W, Siebert R; Molecular Mechanisms in Malignant Lymphomas Network Project.

Haematologica. 2014 Apr;99(4):726-35. doi: 10.3324/haematol.2013.091827. Epub 2013 Oct 31.

17.

The combined expression of VPREB3 and ID3 represents a new helpful tool for the routine diagnosis of mature aggressive B-cell lymphomas.

Soldini D, Georgis A, Montagna C, Schüffler PJ, Martin V, Curioni-Fontecedro A, Martinez A, Tinguely M.

Hematol Oncol. 2014 Sep;32(3):120-5. doi: 10.1002/hon.2094. Epub 2013 Sep 23.

PMID:
24493312
18.

MicroRNAs and lymphomagenesis: a functional review.

Lawrie CH.

Br J Haematol. 2013 Mar;160(5):571-81. doi: 10.1111/bjh.12157. Epub 2012 Dec 4. Review.

PMID:
23205669
19.

The molecular background of aggressive B cell lymphomas as a basis for targeted therapy.

de Jong D, Balagué Ponz O.

J Pathol. 2011 Jan;223(2):274-82. doi: 10.1002/path.2807. Epub 2010 Nov 16. Review.

PMID:
21125680
20.

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR.

Am J Surg Pathol. 2010 Mar;34(3):327-40. doi: 10.1097/PAS.0b013e3181cd3aeb.

Supplemental Content

Support Center